Filing excerpt
In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran autogene (mRNA-4157), our mRNA-based individualized neoantigen therapy, in combination with Merck’s pembrolizumab (KEYTRUDA®)...
Source: Autobound Signal API · 106 signals tracked for Moderna · updated
Get Moderna's live signals in Claude or ChatGPT, or by API
What changed at Moderna this week? Use Autobound signals for modernatx.com.Moderna is advancing its individualized cancer therapy, intismeran, in a major collaboration with Merck, with eight Phase 2 and Phase 3 trials now underway. This complex, multi-trial partnership requires significant investment in clinical trial management systems, data sharing platforms, and coordinated R&D operations between the two pharma giants.
Filing excerpt
In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran autogene (mRNA-4157), our mRNA-based individualized neoantigen therapy, in combination with Merck’s pembrolizumab (KEYTRUDA®)...
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
sec-10kjointVentureGet every 10-K signal for Moderna and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/427aad4f-569f-45f9-8b67-a5a477af7367 returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.
{
"signal_id": "427aad4f-569f-45f9-8b67-a5a477af7367",
"signal_type": "sec-10k",
"signal_subtype": "jointVenture",
"detected_at": "2026-02-24T09:33:59.024+00:00",
"company": {
"name": "Moderna",
"domain": "modernatx.com"
},
"data": {
"detail": "Moderna is advancing its individualized cancer therapy, intismeran, in a major collaboration with Merck, with eight Phase 2 and Phase 3 trials now underway. This complex, multi-trial partnership requires significant investment in clinical trial management systems, data sharing platforms, and coordinated R&D operations between the two pharma giants.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "Moderna deepens collaboration with Merck on mRNA cancer therapy across eight clinical trials",
"excerpts": "In January 2026, we and Merck announced five-year data from the Phase 2b study of intismeran autogene (mRNA-4157), our mRNA-based individualized neoantigen therapy, in combination with Merck’s pembrolizumab (KEYTRUDA®)...",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm",
"filing_date": "2026-02-20",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"vendors_mentioned": [
"Merck"
]
}
}
curl https://signals.autobound.ai/v1/signals/427aad4f-569f-45f9-8b67-a5a477af7367 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"modernatx.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.